文献速递脑血管病

非心源性缺血性卒中早期神经功能恶化的管理策略

Management Strategies for Early Neurological Deterioration in Noncardioembolic Ischemic Stroke.
PubMed 文献 · Stroke · 2025-11-12

该研究基于韩国全国前瞻性多中心卒中登记,纳入2019年1月至2024年8月因卒中进展发生早期神经功能恶化(END)的非心源性缺血性卒中患者3067例,比较保守管理、抗栓方案调整和诱导高血压(iHTN)三种策略。结果显示iHTN组神经功能改善率最高(41.5%),校正后与神经功能改善(aOR 1.55,95%CI 1.25-1.92)和3个月改良Rankin量表良好偏移(aOR 1.24,95%CI 1.03-1.48)相关,抗栓方案调整无显著关联。

要点

  • iHTN与END后神经功能改善及3个月功能预后良好独立相关。
  • 抗栓方案调整与神经功能或功能恢复无显著关联。
  • iHTN的获益在大动脉粥样硬化患者中尤为明显。

核心结论

  • 在因卒中进展发生END的非心源性缺血性卒中患者中,iHTN与有利的临床结局相关。

研究设计与样本

  • 研究分析韩国全国前瞻性多中心卒中登记数据,纳入2019年1月至2024年8月因卒中进展发生END的非心源性缺血性卒中患者3067例。

主要发现

  • 3067例患者中,1840例(60.0%)接受保守管理,747例(24.4%)接受抗栓方案调整,480例(15.7%)接受iHTN治疗。
  • 神经功能改善总体发生率为34.2%,iHTN组最高为41.5%,保守组为32.2%,抗栓调整组为34.4%(P<0.001)。
  • 校正分析显示,与保守管理相比,iHTN增加神经功能改善的 odds(aOR 1.55,95%CI 1.25-1.92)和3个月mRS良好偏移的 odds(aOR 1.24,95%CI 1.03-1.48),尤其在大动脉粥样硬化患者中。
  • 抗栓方案调整与神经功能恢复或功能恢复无显著关联。

关键数值与推荐

  • END定义为符合美国国立卫生研究院卒中量表标准的神经症状新发或加重(总分≥2分或意识/运动子项≥1分)并有影像学确认。
  • 主要结局为神经功能改善(NIHSS评分降低≥2分)和3个月功能结局(mRS有序偏移)。
  • 次要结局包括良好功能恢复(mRS 0-2分)和复合血管事件(死亡、卒中、心肌梗死)。

临床怎么用

  • 对于非心源性缺血性卒中因卒中进展发生END的患者,可考虑采用诱导高血压策略以改善神经功能和3个月功能预后。
  • 抗栓方案调整在该人群中未显示显著获益,临床决策需个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early neurological deterioration (END) is a frequent complication of acute ischemic stroke. Although END worsens clinical outcomes, standardized treatment strategies remain undefined, resulting in variability in clinical practice. This study examines real-world treatment patterns for END and compares the effects of different strategies on neurological and functional outcomes. METHODS: This study analyzed data from a nationwide, prospective, multicenter stroke registry in South Korea, including patients with noncardioembolic stroke who developed END due to stroke progression between January 2019 and August 2024. END was defined as new or worsening neurological symptoms meeting National Institutes of Health Stroke Scale criteria (≥2-point total or ≥1 point in consciousness or motor subscores) with radiological confirmation. Patients were classified into conservative management, antithrombotics change, and induced hypertension (iHTN). The primary outcomes were neurological improvement, defined as a ≥2-point reduction in the National Institutes of Health Stroke Scale score, and 3-month functional outcome measured by modified Rankin Scale ordinal shift. Secondary outcomes included good functional recovery (modified Rankin Scale score, 0-2) and composite vascular events (death, stroke, and myocardial infarction). Multivariable analyses adjusted for age, sex, prestroke modified Rankin Scale, initial National Institutes of Health Stroke Scale score, vascular risk factors, the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, acute thrombolysis, and laboratory covariates. RESULTS: Among 3067 patients with END due to stroke progression, 1840 (60.0%) received conservative management, 747 (24.4%) underwent antithrombotic changes, and 480 (15.7%) were treated with iHTN. Neurological improvement occurred in 34.2% of patients, with the highest in the iHTN group (41.5%) compared with the conservative (32.2%) and antithrombotics change groups (34.4%; P<0.001). In adjusted analyses, iHTN increased the odds of neurological improvement (adjusted odds ratio, 1.55 [95% CI, 1.25-1.92]) and a favorable 3-month modified Rankin Scale shift (adjusted odds ratio, 1.24 95% CI, 1.03-1.48]) compared with conservative management, particularly in patients with large artery atherosclerosis. Antithrombotics change showed no significant association with neurological or functional recovery. CONCLUSIONS: In patients with noncardioembolic ischemic stroke who developed END due to stroke progression, iHTN was associated with favorable clinical outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim H, Kim JT, Lee JS, et al. Management Strategies for Early Neurological Deterioration in Noncardioembolic Ischemic Stroke. Stroke. 2025. PMID: 41221585. doi:10.1161/STROKEAHA.125.053320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。